EBCI Brings Awareness to How Newly Diagnosed Glioblastoma Patients Can Access Imvax’s Clinical Study

The End Brain Cancer Initiative (EBCI) Brings Awareness to How Newly Diagnosed Glioblastoma Patients Can Access Imvax’s Clinical Study

REDMOND, WA, UNITED STATES, January 16, 2024 /EINPresswire.com/ -- The End Brain Cancer Initiative (EBCI) Brings Awareness to How Newly Diagnosed Glioblastoma Patients Can Access Imvax’s Clinical Study

Redmond, WA (January 16, 2024) -- Imvax initiated a Phase 2b study in 93 patients with newly diagnosed Glioblastoma (GBM).

The trial is being conducted at several cancer centers, generally in the Eastern half of the United States. The End Brain Cancer Initiative (EBCI) wants to make patients aware that they can still participate in the trial even if they do not live near one of these sites. Many trial participants have stayed with family or friends in order to be near a participating site for the duration of the trial window.

To be pre-qualified for this clinical trial or obtain additional information, please visit EndBrainCancer.org/Imvax or contact EBCI’s Clinical Research Coordinator/Patient Navigator Shreya Prakash at 425-436-8688 or Shreya@EndBrainCancer.org.

Participating sites include: the Mayo Clinic in FL, Tufts Medical Center in MA, Heny Ford Health
Informed by decades of research, Imvax elegantly turns the complexity of a solid tumor against itself. Imvax's Goldspire™ platform is a personalized, whole tumor-derived, cell-based autologous immunotherapy. It delivers a full tumor antigen payload to patients by combining patient-derived tumor cells and an antisense oligodeoxynucleotide (IMV-001) against insulin-like growth factor type 1 receptor (IGF-1R). The Imvax platform is designed to be incorporated into the standard of care for GBM. To learn more about this trial or be pre-qualified, please visit EndBrainCancer.org/Imvax.

Imvax is a clinical-stage biotechnology company with a unique platform technology, Goldspire™, focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax's most advanced program, IGV-001, is currently being evaluated in a Phase 2b clinical trial in newly diagnosed glioblastoma patients. Imvax's portfolio includes several other programs designed to stimulate a patient's immune system against the entire antigen signature of their tumor.

The End Brain Cancer Initiative is a 501(c)3 non-profit patient organization focused on disease education, awareness, outreach and increasing patient access. The End Brain Cancer Initiative, formerly known as the Chris Elliott Fund, is dedicated to ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain have equal access to advanced diagnostics, treatments, specialists, and clinical trial participation. We believe that IMMEDIATE ACCESS to these options provides this patient community with the best HOPE for survival and sustained quality of life. We partner with industry, patients, researchers, advocacy groups, medical teams, hospital networks and others to educate patients and their caregivers so they can have empowered conversations with medical teams. Learn more about and support the End Brain Cancer Initiative's work and mission at EndBrainCancer.org.

Dellann Elliott Mydland
End Brain Cancer Initiative
+1 425-444-2215
email us here
Visit us on social media:
This press release can be viewed online at: https://www.einpresswire.com/article/681636049

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2024 Newsmatics Inc. All Right Reserved.